Edition:
United States

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

10.00USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$10.00
Open
$9.99
Day's High
$10.00
Day's Low
$9.98
Volume
96,814
Avg. Vol
138,976
52-wk High
$10.20
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period
Friday, 16 Feb 2018 08:00am EST 

Feb 16 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD.SEATTLE GENETICS - ‍REQUIRED WAITING PERIOD UNDER HART-SCOTT-RODINO ACT REGARDING CO'S PROPOSED ACQUISITION OF CASCADIAN THERAPEUTICS EXPIRED ON FEB 15, 2018​.  Full Article

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics
Thursday, 8 Feb 2018 05:39pm EST 

Feb 8 (Reuters) - Cascadian Therapeutics Inc ::SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC..SEATTLE GENETICS - BOARD OF DIRECTORS OF CASCADIAN THERAPEUTICS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS OF CASCADIAN THERAPEUTICS TENDER THEIR SHARES.  Full Article

Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million
Wednesday, 31 Jan 2018 07:25am EST 

Jan 31 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS SAYS IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CASCADIAN THERAPEUTICS MAY BE REQUIRED TO PAY CO FEE OF $17 MILLION - SEC FILING.  Full Article

Seattle Genetics Commences Underwritten Public Offering Of $550 Mln Of Shares
Wednesday, 31 Jan 2018 06:40am EST 

Jan 31 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SEATTLE GENETICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $550.0 MILLION OF SHARES OF ITS COMMON STOCK.SEATTLE GENETICS INC - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND A PORTION OF COSTS OF ACQUISITION OF CASCADIAN THERAPEUTICS.  Full Article

Seattle Genetics To Acquire Cascadian Therapeutics
Wednesday, 31 Jan 2018 06:30am EST 

Jan 31 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE.SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE.DEAL FOR $10.00 PER SHARE IN CASH, OR APPROXIMATELY $614 MILLION..TRANSACTION WAS UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES.SEES REVENUE OF $128 MILLION TO $130 MILLION FOR THREE MONTHS ENDED DEC. 31.SEATTLE GENETICS- UNDER TERMS OF DEAL, CO WILL COMMENCE TENDER OFFER ON/ABT FEB 8 TO BUY ALL OF OUTSTANDING SHARES OF STOCK OF CASCADIAN THERAPEUTICS.SEATTLE GENETICS - ‍IN CONNECTION WITH TRANSACTION, CO HAS SECURED FINANCING COMMITMENT OF $400 MILLION FROM BARCLAYS & JPMORGAN-CHASE BANK​.Q4 REVENUE VIEW $114.2 MILLION -- THOMSON REUTERS I/B/E/S.AS OF DECEMBER 31, 2017, SEATTLE GENETICS HAD APPROXIMATELY $413 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.  Full Article

Cascadian Therapeutics reports Q3 loss per share $0.28
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Cascadian Therapeutics Inc ::Cascadian Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.28.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Cascadian therapeutics - ‍ cash, cash equivalents and investments totaled $113.0 million as of Sept 30, 2017, compared to $62.8 million at Dec 31, 2016​.Cascadian Therapeutics Inc - ‍ cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million​.  Full Article

Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer
Wednesday, 27 Sep 2017 07:00am EDT 

Sept 27 (Reuters) - Cascadian Therapeutics Inc ::Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer.  Full Article

Cascadian Therapeutics Q2 loss per share $0.30
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Cascadian Therapeutics Inc :Cascadian Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.30.Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Cascadian Therapeutics Inc - ‍expects operating expenses in 2017 to be slightly higher than in 2016​.Cascadian Therapeutics Inc - ‍cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million​.  Full Article

Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe
Tuesday, 11 Jul 2017 08:00am EDT 

July 11 (Reuters) - Cascadian Therapeutics Inc :Cascadian Therapeutics announces positive regulatory update for tucatinib in Europe.Cascadian Therapeutics Inc - ‍announced outcome of discussions with European Medicines Agency (EMA) regarding development of tucatinib​.Cascadian Therapeutics - received confirmation that positive results from her2climb could serve as single registrational trial for submission of MAA to EMA, potential marketing approval​.Cascadian Therapeutics - ‍site, patient enrollment currently ahead of schedule in n. America, Poised to begin enrolling patients in her2climb in other countries​.  Full Article

Cascadian Therapeutics’ tucatinib, receives orphan drug designation from FDA
Thursday, 8 Jun 2017 08:00am EDT 

June 8 (Reuters) - Cascadian Therapeutics Inc :Cascadian therapeutics' lead candidate, tucatinib, receives orphan drug designation from fda for treatment of breast cancer patients with brain metastases‍​.  Full Article